Search Results
Jan 28, 2026, 09:15 ET Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
ateganosine into pivotal development with high probability of technical success based on exceptional efficacy data in third-line non-small cell lung cancer. The telomere-targeting agent secured FDA Fast Track designation and represents the first and only direct telomere-targeting anticancer
More news about: USA News Group
Jan 28, 2026, 08:30 ET IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Jan 28, 2026, 08:00 ET ReDS-SAFE HF II Trial Initiated - Large Randomized Controlled Study to Expand Evidence for ReDS-Guided Heart Failure Management
JACC: Heart Failure. These findings highlighted the clinical value of non-invasive, quantitative lung fluid assessment to support better decision-making in hospitalized heart-failure patients.About the ReDS™ Pro SystemThe ReDS™ Pro
More news about: Sensible Medical
Jan 28, 2026, 07:00 ET Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering,
More news about: Insmed Incorporated
Jan 28, 2026, 00:01 ET Lung Association Report: Cuts to Federal Tobacco Prevention Efforts Put U.S. Lives at Risk
Lung.org/sotc.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Jan 27, 2026, 14:48 ET Momcozy Donates Wearable Breast Pumps to The King's Daughters Milk Bank at Children's Hospital of The King's Daughters
up to 80% and significantly decrease the occurrence of complications such as life threatening bowel infections, severe vision impairment, and chronic lung disease."We are honored to be working with The King's Daughters Milk Bank at CHKD to help make human milk donation and pumping more accessible
More news about: Momcozy
Jan 27, 2026, 12:00 ET New indication in children from birth for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission
of:the brain, spine, and associated tissues of the central nervous system (CNS);the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.For these indications, an MRI examination with Elucirem™ requires half the conventional dose compared
More news about: Guerbet
Jan 27, 2026, 11:00 ET Higginbotham Expands Prevention with New Wellness Option: Function Health
advanced MRI can detect cancers, unruptured aneurysms, endometriosis, signs of stroke, etc., while the CT scan can identify lung cancer, plaque in the heart, etc. All data is integrated into a single intelligent interface, giving each member a personalized view of their health
More news about: Higginbotham
Jan 27, 2026, 10:50 ET Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks
cancer care."The companies have eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma. Moderna and Merck plan to present further data from follow-up analyses of the study's
More news about: Equity Insider
Jan 27, 2026, 10:14 ET AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market
planned SDK access will support advanced imaging workflows across multiple presets including abdominal, cardiac, obstetric, musculoskeletal, vascular, and lung imaging. Butterfly Network continues expanding its Butterfly Garden and Ultrasound-on-Chip co-development programs, with availability and technical
More news about: USA News Group
Jan 27, 2026, 08:46 ET The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age
of the brain, spine, and associated tissues of the central nervous system, as well as contrast-enhanced MRI of the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.(3)On 11 December 2025, the CHMP adopted in EU a positive opinion for the extension of the approved
More news about: Bracco Group
Jan 27, 2026, 08:30 ET Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Jan 27, 2026, 08:00 ET Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
involving the lung, liver, bone, and lymph nodes, initiated treatment with paxalisib (30 mg daily) in combination with pembrolizumab and gemcitabine/carboplatin in October 2025. Following three treatment cycles, imaging demonstrated a partial response, including complete resolution of a target lung lesion and
More news about: Kazia Therapeutics Limited
Jan 27, 2026, 07:51 ET Brayton Purcell LLP Releases New Podcast Episode Examining Cal/OSHA Testimony and Federal HR 5437 Hearing
Representative Hank Johnson, offered forceful statements expressing deep concern for affected workers. They noted that many young workers now require double‑lung transplants and emphasized that silicosis linked to artificial stone fabrication is entirely preventable. Their testimony highlighted that artificial
More news about: Brayton Purcell LLP
Jan 27, 2026, 03:00 ET Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
into a licensing agreement with Black Diamond Therapeutics to develop and commercialize a targeted therapy for solid tumors, including non-small cell lung cancer. Additionally, the acquisition of a precision therapy from Chinese biopharmaceutical company BioNova Pharmaceuticals Ltd also enabled the Group
More news about: Servier
Jan 27, 2026, 03:00 ET Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
into a licensing agreement with Black Diamond Therapeutics to develop and commercialize a targeted therapy for solid tumors, including non-small cell lung cancer. Additionally, the acquisition of a precision therapy from Chinese biopharmaceutical company BioNova Pharmaceuticals Ltd also enabled the Group
More news about: Servier
Jan 27, 2026, 02:00 ET The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age
of the brain, spine, and associated tissues of the central nervous system, as well as contrast-enhanced MRI of the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.(3)On 11 December 2025, the CHMP adopted in EU a positive opinion for the extension of the approved
More news about: Bracco Group
Jan 26, 2026, 17:31 ET RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
Non-small Cell Lung Cancer Clinical Trial AnalysisNon-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies,
More news about: DelveInsight Business Research, LLP
Jan 26, 2026, 17:27 ET 4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease with significantly greater precision.These insights help pulmonologists, radiologists and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform
More news about: 4DMedical
Jan 26, 2026, 11:00 ET ASCP and Pfizer Launch Request for Proposals to Fund Quality Improvement Projects Advancing Biomarker Testing in mCRC
in some of the world's most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.About Pfizer:
More news about: American Society of Clinical Pathology
Jan 26, 2026, 09:13 ET CancerIQ and Azra AI Partner to Support Growing Lung Cancer Screening Programs
follow-up needs change, CancerIQ helps lung cancer screening programs improve patient selection, enrich pre-test probability, and reduce manual tracking, outreach, and follow-up effort for navigation and care coordination teams."For cancer center leaders, lung cancer screening has grown from an isolated
More news about: CancerIQ, Inc.
Jan 26, 2026, 08:01 ET START Appoints Dr. Navid Hafez as Director of Clinical Research at Its New Los Angeles Site
100,000 new cancer diagnoses annually. LACN cares for more than 14,000 new cancer patients every year spanning all major disease areas, from breast, lung, and hematologic malignancies to colorectal, prostate, and other solid tumors, creating an unparalleled opportunity to bring "Hope Through Access" and
More news about: The START Center for Cancer Research
Jan 23, 2026, 15:24 ET Statement from Dr. Larry Schlesinger, President & CEO, Texas Biomedical Research Institute
tuberculosis and lung biology. TB is the deadliest infectious disease in the world.About Texas Biomedical Research InstituteTexas Biomedical Research
More news about: Texas Biomedical Research Institute
Jan 22, 2026, 12:30 ET Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that the key results from the Phase 2b CORAL trial of oral nalbuphine ER
More news about: Trevi Therapeutics, Inc.
Jan 22, 2026, 10:22 ET Florida Cancer Specialists & Research Institute Among First in Florida to Trial Next-Generation Immunotherapy for Castration-Resistant Prostate Cancer
trial. FCS offers step-up dosing and maintenance therapy with FDA-approved bispecific drugs to treat recurring and resistant blood cancers and small cell lung cancer."Treatment-resistant cancers pose a major challenge in medicine," said
More news about: Florida Cancer Specialists & Research Institute